| Outcome Measures: |
Primary: Gemigliptin AUCτ,ss Geometric Mean Ratio (and 90%CI), AUCτ,ss Geometric Mean Ratio for gemigliptin when administered concomitanty with metformin (test) to its administration alone (reference), At steady state, on the sixth planned treatment day | Secondary: Gemigliptin Cmax,ss Geometric Mean Ratio (and 90%CI), Cmax,ss Geometric Mean Ratio for gemigliptin when administered concomitanty with metformin (test) to its administration alone (reference), At steady state, on the sixth planned treatment day|Metformin AUCτ,ss Geometric Mean Ratio (and 90%CI), AUCτ,ss Geometric Mean Ratio for metformin when administered concomitanty with metformin (test) to its administration alone (reference), At steady state, on the sixth planned treatment day|Metformin Cmax,ss Geometric Mean Ratio (and 90%CI), Cmax,ss Geometric Mean Ratio for metformin when administered concomitanty with metformin (test) to its administration alone (reference), At steady state, on the sixth planned treatment day|Ctrough,ss, Lowest plasma concentration prior to the next dose administration at steady state, At steady state, on the sixth planned treatment day|Aeτ,ss, cumulative amount of drug excreted in the urine during a dosing interval, At steady state, on the sixth planned treatment day|CLss/F, Apparent drug clearance, At steady state, on the sixth planned treatment day|CLR,ss, Renal drug clearance, At steady state, on the sixth planned treatment day|MR, Metabolic ratio, At steady state, on the sixth planned treatment day|Tmax, Time to maximum plasma concentration at steady state, At steady state, on the sixth planned treatment day | Other: Incidence of treatment-emergent adverse events, Incidence of adverse events occuring during the exposure to the study medications, From the first pre-treatment admission date, trough the 39 days required for completion of the planned treatment/sampling and washout periods up to and including the post-study safety visit, conducted at study day 44
|
